HC Wainwright reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX - Free Report) in a research note released on Thursday morning, Benzinga reports. They currently have a $9.00 target price on the stock.
A number of other analysts have also weighed in on the stock. Wedbush restated an outperform rating and set a $5.00 target price (up from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th. Needham & Company LLC restated a buy rating and set a $12.00 target price on shares of G1 Therapeutics in a research note on Wednesday.
View Our Latest Analysis on GTHX
G1 Therapeutics Trading Up 7.5 %
NASDAQ GTHX traded up $0.31 during trading hours on Thursday, reaching $4.44. The company had a trading volume of 730,958 shares, compared to its average volume of 1,255,023. The stock has a 50-day moving average of $3.90 and a 200 day moving average of $3.06. G1 Therapeutics has a 1-year low of $1.08 and a 1-year high of $5.00. The company has a current ratio of 3.87, a quick ratio of 3.45 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $232.26 million, a P/E ratio of -4.67 and a beta of 1.71.
G1 Therapeutics (NASDAQ:GTHX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The business had revenue of $14.48 million for the quarter, compared to analysts' expectations of $15.21 million. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. During the same quarter last year, the company earned ($0.53) earnings per share. As a group, research analysts anticipate that G1 Therapeutics will post -0.64 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the sale, the insider now directly owns 169,938 shares of the company's stock, valued at $785,113.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 8.23% of the company's stock.
Institutional Investors Weigh In On G1 Therapeutics
Several hedge funds have recently modified their holdings of GTHX. Raymond James & Associates lifted its holdings in shares of G1 Therapeutics by 16.9% during the third quarter. Raymond James & Associates now owns 925,776 shares of the company's stock worth $1,333,000 after purchasing an additional 133,662 shares during the period. Curi Wealth Management LLC lifted its holdings in shares of G1 Therapeutics by 17.8% during the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company's stock worth $102,000 after purchasing an additional 10,700 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of G1 Therapeutics during the third quarter worth $189,000. Algert Global LLC acquired a new stake in shares of G1 Therapeutics during the third quarter worth $98,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of G1 Therapeutics by 68.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company's stock worth $294,000 after purchasing an additional 82,879 shares during the period. 24.21% of the stock is owned by institutional investors and hedge funds.
About G1 Therapeutics
(
Get Free Report)
G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
Further Reading
Before you consider G1 Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and G1 Therapeutics wasn't on the list.
While G1 Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
